Sobi Unveils Groundbreaking Gout Research at ACR Convergence 2026
Sobi Unveils Groundbreaking Gout Research at ACR Convergence 2026
On November 3, 2026, Sobi® (STO: SOBI) declared their participation in ACR Convergence 2026, the prestigious annual meeting hosted by the American College of Rheumatology in Orlando, Florida, from November 6 to 11. During this event, the company will present six pioneering abstracts that spotlight their research efforts in the realm of gout management, particularly focusing on pozdeutinurad (AR882) and a novel combination therapy of nanoencapsulated sirolimus with pegadricase (NASP).
Significance of Gout Research
Gout, known as one of the most prevalent forms of systemic inflammatory arthritis, arises from elevated levels of serum urate (SU), resulting in the formation of monosodium urate crystals that cause acute joint pain and inflammation. This painful condition significantly disrupts the daily lives of those affected, triggering flares and leading to joint damage if left unmanaged. The need for effective treatments remains critical, especially for patients experiencing uncontrolled gout, characterized by persistent and debilitating symptoms despite ongoing urate-lowering therapies.
Dr. Lydia Abad-Franch, MD, who oversees Research and Development as well as Medical Affairs at Sobi, emphasized the profound effect gout has on patients' quality of life, especially when not adequately controlled. She stated, "Through our clinical development programs and patient-centered research, we aim to elevate our understanding of these complexities and meet the treatment needs of gout patients more effectively."
Presentation Highlights
Among the anticipated presentations at ACR Convergence are key findings from the Phase 3 REDUCE-2 study focused on pozdeutinurad (AR882). Additionally, data will be shared from the DISSOLVE I and II Phase 3 trials investigating NASP's efficacy in managing uncontrolled gout. These findings include:
- - Oral Presentation: Investigating the treatment impact of URAT1 Inhibitor Pozdeutinurad (AR882) in a robust Phase 3, double-blind, randomized study aimed at lowering serum urate levels. Scheduled for delivery on November 11, 2026, this presentation will underscore pozdeutinurad's promising clinical benefits.
- - Poster Presentations: This will cover evaluations from DISSOLVE I/II, concerning the determined stopping rules for NASP in patients dealing with uncontrolled gout. Additional analyses will explore the association between clinical manifestations of gout and patient-reported outcomes based on findings from a real-world survey conducted in the United States.
- - Other noteworthy posters aim to assess varying patient preferences toward uricase treatments and explore the correlation between tophi presence, elevated serum urate levels, and overall health-related quality of life.
These presentations offer a unique glimpse into the ongoing efforts aimed at transforming how gout is treated within the healthcare system, providing hope to millions dealing with the chronic and painful condition.
Investigational Drugs in Focus
Pozdeutinurad (AR882) is being developed as a once-daily oral medication that selectively inhibits URAT1, a key transporter involved in urate reabsorption. Initial Phase 2 studies showcased its potential in significantly lowering serum urate and promoting the dissolution of tophi, combined with a favorable safety profile. Continuing research includes two pivotal 12-month randomized, double-blind, placebo-controlled Phase 3 studies — REDUCE 1 and REDUCE 2 — which together aim to confirm its efficacy in patients battling uncontrolled gout.
NASP, on the other hand, represents an innovative yet investigational therapy that works through a two-component infusion regimen aimed at managing uncontrolled gout. This novel treatment pairs tolerogenic nanoencapsulated sirolimus with pegadricase to mitigate the formation of anti-drug antibodies while effectively reducing serum urate levels for improved patient outcomes.
The Path Forward
As Sobi advances its commitment to transforming patient care through groundbreaking research, the data showcased at ACR Convergence 2026 will surely play a pivotal role in reshaping the management strategies deployed for gout patients. Given the substantial impact uncontrolled gout can have on quality of life, the promise of new therapeutic avenues is a hopeful development for both patients and healthcare providers alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.